Skip to main content

Health Care Economics

Expert Perspectives

conference coverage


Conference Coverage
10/18/2024
Explore the implications of the CY 2025 Medicare Part D Redesign and the Inflation Reduction Act with AMCP Nexus 2024 session speakers, addressing successes and challenges faced by stakeholders as they prepare for significant changes ahead.
Explore the implications of the CY 2025 Medicare Part D Redesign and the Inflation Reduction Act with AMCP Nexus 2024 session speakers, addressing successes and challenges faced by stakeholders as they prepare for significant changes ahead.
Explore the implications of the...
10/18/2024
First Report Managed Care
Conference Coverage
10/16/2024
Researchers at AMCP Nexus 2024 explored the cost-effectiveness of Midomafetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) in US health care settings, with findings suggesting it may be a more cost-effective...
Researchers at AMCP Nexus 2024 explored the cost-effectiveness of Midomafetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) in US health care settings, with findings suggesting it may be a more cost-effective...
Researchers at AMCP Nexus 2024...
10/16/2024
First Report Managed Care
Conference Coverage
10/14/2024
Multigene panel testing can increase eligibility for targeted therapy in lung and colorectal cancer patients while only representing a small portion of total care costs according to research presented at AMCP Nexus 2024.
Multigene panel testing can increase eligibility for targeted therapy in lung and colorectal cancer patients while only representing a small portion of total care costs according to research presented at AMCP Nexus 2024.
Multigene panel testing can...
10/14/2024
First Report Managed Care
Conference Coverage
09/17/2024
In July 2024, the Federal Trade Commission (FTC) published an interim report discussing the impact that pharmacy benefit managers (PBMs) have on the accessibility and affordability of drugs in the US. The report was issued as part of an...
In July 2024, the Federal Trade Commission (FTC) published an interim report discussing the impact that pharmacy benefit managers (PBMs) have on the accessibility and affordability of drugs in the US. The report was issued as part of an...
In July 2024, the Federal Trade...
09/17/2024
First Report Managed Care
Conference Coverage
05/20/2024
Matt Dickinson, PharmD, MBA, Alnylam Pharmaceuticals, led a panel to highlight payer strategies for managing rare and specialty disease products and how they continue to evolve based on Alnylam Pharmaceuticals’ 2023 Rare and Specialty Trend...
Matt Dickinson, PharmD, MBA, Alnylam Pharmaceuticals, led a panel to highlight payer strategies for managing rare and specialty disease products and how they continue to evolve based on Alnylam Pharmaceuticals’ 2023 Rare and Specialty Trend...
Matt Dickinson, PharmD, MBA,...
05/20/2024
First Report Managed Care
Conference Coverage
05/02/2024
The rapid pace of innovation, rising costs of prescription drugs, and the need for transparency to ensure access and affordability in the pharmaceutical industry are discussed in a session at Asembia 2024.
The rapid pace of innovation, rising costs of prescription drugs, and the need for transparency to ensure access and affordability in the pharmaceutical industry are discussed in a session at Asembia 2024.
The rapid pace of innovation,...
05/02/2024
First Report Managed Care
Conference Coverage
04/11/2024
“These data show that the burden of care for NASH is substantial, and compared with those without progression, the annual costs per person with progression are at least 2-fold higher, with the gap increasing over time,” said researchers that...
“These data show that the burden of care for NASH is substantial, and compared with those without progression, the annual costs per person with progression are at least 2-fold higher, with the gap increasing over time,” said researchers that...
“These data show that the burden...
04/11/2024
First Report Managed Care
Conference Coverage
06/08/2023
A significant portion of drug approvals for nonhematologic solid cancers in the last 12 years were for indications which added to existing regimens, which could increase costs and exposure to side effects, researchers said.
A significant portion of drug approvals for nonhematologic solid cancers in the last 12 years were for indications which added to existing regimens, which could increase costs and exposure to side effects, researchers said.
A significant portion of drug...
06/08/2023
First Report Managed Care
Conference Coverage
04/11/2023
Increasing next-generation sequencing testing for metastatic colorectal cancer may help optimize therapy selection without significantly increasing costs for US payers, researchers said.
Increasing next-generation sequencing testing for metastatic colorectal cancer may help optimize therapy selection without significantly increasing costs for US payers, researchers said.
Increasing next-generation...
04/11/2023
First Report Managed Care
Conference Coverage
03/24/2023
The session highlighted key obstacles to real-time benefit check adoption by providers and included advice for payers to overcome barriers.
The session highlighted key obstacles to real-time benefit check adoption by providers and included advice for payers to overcome barriers.
The session highlighted key...
03/24/2023
First Report Managed Care